Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

被引：7
|
作者：
Nichols, G. [1 ]
Mills, A. [2 ]
Grossberg, R. [3 ]
Lazzarin, A. [4 ]
Maggiolo, F. [5 ]
Molina, J. [6 ]
Pialoux, G. [7 ]
Wright, D. [8 ]
Ait-Khaled, M. [9 ]
Huang, J. [10 ]
Vavro, C. [1 ]
Wynne, B. [11 ]
Yeo, J. [9 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Anthony Mills MD Inc, Los Angeles, CA USA
[3] Montefiore Med Ctr, New York, NY USA
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[6] Hosp St Louis, Paris, France
[7] Hosp Tenon, Paris, France
[8] Cent Texas Clin Res, Austin, TX USA
[9] GlaxoSmithKline, London, England
[10] GlaxoSmithKline, Mississauga, ON, Canada
[11] GlaxoSmithKline, Philadelphia, PA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18112
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [41] Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
    Rubin, David T.
    Sands, Bruce E.
    Lichtenstein, Gary R.
    Baker, Thomas
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Miao, Ye
    Zhang, Hongyan
    Nancey, Stephane
    Allegretti, Jessica R.
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S672 - S673
  • [42] Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir plus Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
    van Wyk, Jean
    Orkin, Chloe
    Rubio, Rafael
    Bogner, Johannes
    Baker, David
    Khuong-Josses, Marie-Aude
    Parks, David
    Angelis, Konstantinos
    Kahl, Lesley P.
    Matthews, Jessica
    Wang, Ruolan
    Underwood, Mark
    Wynne, Brian
    Nascimento, Maria-Claudia
    Vandermeulen, Kati
    Gartland, Martin
    Smith, Kimberly Y.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 325 - 330
  • [43] An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
    Lee A. Evitt
    Sakina Nanji
    Richard A. Grove
    Chinyere Okoli
    Jean van Wyk
    Sonya J. Snedecor
    AIDS Research and Therapy, 20
  • [44] Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn's Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies
    Danese, Silvio
    Afzali, Anita
    Panaccione, Remo
    Panes, Julian
    Reinisch, Walter
    Terry, Natalie A.
    Salese, Leonardo
    Van Rampelbergh, Rian
    Wan, Kitty Y. Y.
    Yang, Zijiang
    Johanns, Jewel
    Zmudzinski, Marcin
    Zittan, Eran
    Matsuoka, Katsuyoshi
    Jairath, Vipul
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S741 - S742
  • [45] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
    Daar, Eric S.
    Dejesus, Edwin
    Ruane, Peter
    Crofoot, Gordon
    Oguchi, Godson
    Creticos, Catherine
    Rockstroh, Juergen K.
    Molina, Jean-Michel
    Koenig, Ellen
    Liu, Ya-Pei
    Custodio, Joseph
    Andreatta, Kristen
    Graham, Hiba
    Cheng, Andrew
    Martin, Hal
    Quirk, Erin
    LANCET HIV, 2018, 5 (07): : E347 - E356
  • [46] AN INTEGRATED APPROACH TO DEVELOP BELATACEPT DOSING REGIMEN FOR A PHASE 3 (P3) STUDY IN STABLE KIDNEY TRANSPLANT RECIPIENTS (KTR) SWITCHED FROM CALCINEURIN INHIBITOR (CNI)-BASED REGIMENS
    Shen, J.
    Lee, S.
    Townsend, R.
    Zhou, Z.
    Roy, A.
    Jones-Burton, C.
    Heifets, M.
    Harler, M.
    Masson, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S107 - S108
  • [47] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
    Kavanaugh, Arthur
    Gladman, Dafna
    Edwards, Christopher J.
    Poder, Airi
    Liote, Frederic
    Bird, Paul A.
    Schett, Georg
    McIlraith, Melissa
    Teng, Lichen
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [48] Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome-Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)
    Jeppesen, Palle B.
    Pertkiewicz, Marek
    Seidner, Douglas L.
    O'Keefe, Stephen
    Heinze, Hartmut
    Joelsson, Bo
    GASTROENTEROLOGY, 2011, 140 (05) : S146 - S146
  • [49] Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
    Kishimoto, Mitsumasa
    Taniguchi, Atsuo
    Fujishige, Ayako
    Kaneko, Shuhei
    Haemmerle, Sibylle
    Porter, Brian O.
    Kobayashi, Shigeto
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 132 - 140
  • [50] Phase 3 study of fostemsavir in heavily treatment experienced HIV-1 infected subjects: day 8 and week 24 primary efficacy and safety results (Study 205888, formerly AI438-047)
    Kozal, M.
    Aberg, J.
    Pialoux, G.
    Cahn, P.
    Thompson, M.
    Molina, J-M
    Grinsztejn, B.
    Diaz, R.
    Lazzarin, A.
    Gummel, M.
    Pierce, A.
    Ackerman, P.
    Llamoso, C.
    Lataillade, M.
    HIV MEDICINE, 2018, 19 : S27 - S27
12345